Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study

Amitava Banerjee, Laura Pasea, Steve Harris, Arturo Gonzalez-Izquierdo, Ana Torralbo, Laura Shallcross, Mahdad Noursadeghi, Deenan Pillay, Neil Sebire, Chris Holmes, Christina Pagel, Wai Keong Wong, Claudia Langenberg, Bryan Williams, Spiros Denaxas, Harry Hemingway, Amitava Banerjee, Laura Pasea, Steve Harris, Arturo Gonzalez-Izquierdo, Ana Torralbo, Laura Shallcross, Mahdad Noursadeghi, Deenan Pillay, Neil Sebire, Chris Holmes, Christina Pagel, Wai Keong Wong, Claudia Langenberg, Bryan Williams, Spiros Denaxas, Harry Hemingway

Abstract

Background: The medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19) pandemic has unknown effects on overall population mortality. Previous models of population mortality are based on death over days among infected people, nearly all of whom thus far have underlying conditions. Models have not incorporated information on high-risk conditions or their longer-term baseline (pre-COVID-19) mortality. We estimated the excess number of deaths over 1 year under different COVID-19 incidence scenarios based on varying levels of transmission suppression and differing mortality impacts based on different relative risks for the disease.

Methods: In this population-based cohort study, we used linked primary and secondary care electronic health records from England (Health Data Research UK-CALIBER). We report prevalence of underlying conditions defined by Public Health England guidelines (from March 16, 2020) in individuals aged 30 years or older registered with a practice between 1997 and 2017, using validated, openly available phenotypes for each condition. We estimated 1-year mortality in each condition, developing simple models (and a tool for calculation) of excess COVID-19-related deaths, assuming relative impact (as relative risks [RRs]) of the COVID-19 pandemic (compared with background mortality) of 1·5, 2·0, and 3·0 at differing infection rate scenarios, including full suppression (0·001%), partial suppression (1%), mitigation (10%), and do nothing (80%). We also developed an online, public, prototype risk calculator for excess death estimation.

Findings: We included 3 862 012 individuals (1 957 935 [50·7%] women and 1 904 077 [49·3%] men). We estimated that more than 20% of the study population are in the high-risk category, of whom 13·7% were older than 70 years and 6·3% were aged 70 years or younger with at least one underlying condition. 1-year mortality in the high-risk population was estimated to be 4·46% (95% CI 4·41-4·51). Age and underlying conditions combined to influence background risk, varying markedly across conditions. In a full suppression scenario in the UK population, we estimated that there would be two excess deaths (vs baseline deaths) with an RR of 1·5, four with an RR of 2·0, and seven with an RR of 3·0. In a mitigation scenario, we estimated 18 374 excess deaths with an RR of 1·5, 36 749 with an RR of 2·0, and 73 498 with an RR of 3·0. In a do nothing scenario, we estimated 146 996 excess deaths with an RR of 1·5, 293 991 with an RR of 2·0, and 587 982 with an RR of 3·0.

Interpretation: We provide policy makers, researchers, and the public a simple model and an online tool for understanding excess mortality over 1 year from the COVID-19 pandemic, based on age, sex, and underlying condition-specific estimates. These results signal the need for sustained stringent suppression measures as well as sustained efforts to target those at highest risk because of underlying conditions with a range of preventive interventions. Countries should assess the overall (direct and indirect) effects of the pandemic on excess mortality.

Funding: National Institute for Health Research University College London Hospitals Biomedical Research Centre, Health Data Research UK.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Prevalence of underlying conditions associated with high mortality in COVID-19 infection (n=3 862 012)
Figure 2
Figure 2
Baseline 1-year mortality in England according to underlying conditions (n=3 862 012)
Figure 3
Figure 3
Baseline 1-year mortality in England according to number of underlying conditions, age category, and sex (n=3 862 012)
Figure 4
Figure 4
Estimated number of excess deaths at 1 year in the UK at different infection rates and relative risks for the impact of COVID-19 (A) Total deaths. (B) Detailed breakdown of deaths across different categories. RR=relative risk.
Figure 4
Figure 4
Estimated number of excess deaths at 1 year in the UK at different infection rates and relative risks for the impact of COVID-19 (A) Total deaths. (B) Detailed breakdown of deaths across different categories. RR=relative risk.

References

    1. Spiegelhalter D. How much ‘normal’ risk does Covid represent? Medium. March 21, 2020.
    1. Ferguson NM, Laydon D, Nedjati-Gilani G. Imperial College; London: March 16, 2020. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand.
    1. WHO . World Health Organization; Geneva: Feb 16–24, 2020. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19)
    1. Yang J, Zheng Y, Gou X. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 doi: 10.1016/j.ijid.2020.03.017. published online March 12.
    1. WHO Emergency Committee . World Health Organization; Geneva: Jan 30, 2020. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)
    1. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 doi: 10.1001/jama.2020.4683. published online March 23.
    1. Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Bialek S, Boundy E, Bowen V. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:343–346.
    1. Oke J, Heneghan C. CEBM Research; April 6, 2020. Global COVID-19 case fatality rates.
    1. Office for National Statistics Deaths registered weekly in England and Wales, provisional: week ending 3 April 2020. April 14, 2020.
    1. US Centers for Disease Control and Prevention Coronavirus disease 2019 (COVID-19). People who are at higher risk. April 15, 2020.
    1. Public Health England Guidance on social distancing for everyone in the UK. March 30, 2020.
    1. UK Government Major new measures to protect people at highest risk from coronavirus. March 21, 2020.
    1. Denaxas S, Gonzalez-Izquierdo A, Direk K. UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER. J Am Med Inform Assoc. 2019;26:1545–1559.
    1. Kuan V, Denaxas S, Gonzalez-Izquierdo A. A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. Lancet Digital Health. 2019;1:e63–e77.
    1. Rapsomaniki E, Timmis A, George J. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383:1899–1911.
    1. Pikoula M, Quint JK, Nissen F, Hemingway H, Smeeth L, Denaxas S. Identifying clinically important COPD sub-types using data-driven approaches in primary care population based electronic health records. BMC Med Inform Decis Mak. 2019;19:86.
    1. Hurst JR, Dickhaus J, Maulik PK. Global Alliance for Chronic Disease researchers' statement on multimorbidity. Lancet Glob Health. 2018;6:e1270–e1271.
    1. Bozkurt B, Kovacs R, Harrington R. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. March 17, 2020.
    1. US Food and Drug Administration FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. March 19, 2020.
    1. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020 doi: 10.1016/S1473-3099(20)30195-X. published online March 12.
    1. Lintern S. Coronavirus could kill half a million Britons and infect 80% of UK population, government documents indicate. The Independent. Feb 26, 2020
    1. Office for National Statistics Deaths by single year of age tables, UK. Jan 17, 2020.
    1. United Nations Population Fund World population dashboard.
    1. Cyranoski D. What China's coronavirus response can teach the rest of the world. Nature. 2020;579:479–480.
    1. Yusuf S, Islam S, Chow CK. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet. 2011;378:1231–1243.
    1. Hemingway H, Croft P, Perel P. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ. 2013;346
    1. Al Sallakh MA, Vasileiou E, Rodgers SE, Lyons RA, Sheikh A, Davies GA. Defining asthma and assessing asthma outcomes using electronic health record data: a systematic scoping review. Eur Respir J. 2017;49
    1. Rapsomaniki E, Thuresson M, Yang E. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin Outcomes. 2016;2:172–183.
    1. Harris S, Shi S, Brealey D. Critical Care Health Informatics Collaborative (CCHIC): data, tools and methods for reproducible research: a multi-centre UK intensive care database. Int J Med Inform. 2018;112:82–89.
    1. Kaura A, Panoulas V, Glampson B. Association of troponin level and age with mortality in 250 000 patients: cohort study across five UK acute care centres. BMJ. 2019;367
    1. Fenichel EP. Economic considerations for social distancing and behavioral based policies during an epidemic. J Health Econ. 2013;32:440–451.
    1. BBC News Coronavirus: UK deaths double in 24 hours. March 14, 2020.

Source: PubMed

3
Abonnieren